Asia-Pacific Journal of Ophthalmology最新文献

{"title":"Mechanisms of supratarsal crease formation in incisional blepharoplasty among Asian patients: A review","authors":"Alene Ker Hsin Ng ,&nbsp;Don O. Kikkawa ,&nbsp;Ho-Seok Sa ,&nbsp;Pimkwan Jaru-ampornpan ,&nbsp;Kelvin Kam Lung Chong ,&nbsp;Hunter Kwok Lai Yuen","doi":"10.1016/j.apjo.2026.100326","DOIUrl":"10.1016/j.apjo.2026.100326","url":null,"abstract":"<div><div>The formation of a lasting and natural supratarsal crease remains the primary goal of incisional double-eyelid blepharoplasty in Asian patients. Surgical techniques have progressed from direct dermis-tarsus fixation to various methods designed to create a more dynamic supratarsal crease. Although these variations exist, differences in crease-formation methods are often described without clear explanations of their underlying mechanisms. The aim of this review is to provide a detailed comparison of the different structural mechanisms underlying supratarsal crease formation, with emphasis on full-incisional techniques commonly performed in Asian patients. A PubMed literature search of English-language articles published between January 2010 to December 2025 was conducted. Nineteen studies met the inclusion criteria and their techniques were evaluated based on key characteristics of supratarsal crease formation. These include: creation of primary tissue connections, fixation strategy, handling of tissue structures, postoperative crease behavior, and reported limitations. Four biomechanical groups based on the dominant fixation plane were identified. A clearer understanding of the different techniques in supratarsal crease formation can help guide surgical decision-making and improve functional and aesthetic outcomes in Asian supratarsal crease-forming blepharoplasty.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"15 3","pages":"Article 100326"},"PeriodicalIF":4.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147855875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ZVS101e: AAV-mediated gene replacement therapy for Bietti crystalline corneoretinal dystrophy (BCD)","authors":"Liping Yang ,&nbsp;Wang Li ,&nbsp;Jinlu Zhang ,&nbsp;Shaohong Chen ,&nbsp;Jing Qiao ,&nbsp;Baoyuan Qu ,&nbsp;Fan Zhang ,&nbsp;Xiuping Shen ,&nbsp;Hiu Ying Enne Leung ,&nbsp;Dennis S.C. Lam","doi":"10.1016/j.apjo.2026.100320","DOIUrl":"10.1016/j.apjo.2026.100320","url":null,"abstract":"<div><div>Bietti crystalline corneoretinal dystrophy (BCD), a rare autosomal recessive retinal degenerative disease caused by cytochrome P450 family 4 subfamily V member 2 <em>(CYP4V2)</em> mutations, leads to progressive vision loss and blindness and exhibits a high prevalence in East Asia. Adeno-associated virus (AAV)-mediated gene replacement therapy has emerged as the most promising therapeutic strategy for BCD, considering its success in monogenic retinal diseases and unique advantages for retinal delivery. This review provides valuable insights into the translational journey of BCD gene therapy to accelerate research progress, facilitate the sharing of resources and expertise, and overcome the complex challenges associated with the development of therapies for rare diseases. It also offers a comprehensive overview of the current progress and future prospects of ZVS101e and provides a valuable resource to researchers, clinicians, and patients interested in the development of gene therapy for inherited retinal diseases. Additionally, it highlights the translational potential of AAV-based therapy in addressing unmet medical needs, such as BCD, and emphasizes the crucial role of industry–university–research collaboration in driving innovative therapies from the laboratory to clinical practice. Potential use of suprachoroidal space injection to deliver the gene materials in treating BCD is also discussed.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"15 3","pages":"Article 100320"},"PeriodicalIF":4.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147760744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel drug development for geographic atrophy","authors":"Hiu Ying Enne Leung ,&nbsp;Jingfa Zhang ,&nbsp;Nishant V. Radke ,&nbsp;Shaoju Gan ,&nbsp;Shiyu Yao ,&nbsp;Zhiqiang Wang ,&nbsp;Jiaxuan Li ,&nbsp;Xiangsheng Liu ,&nbsp;Victor Chong ,&nbsp;Xie Wang ,&nbsp;Weihong Tan ,&nbsp;Dennis S.C. Lam","doi":"10.1016/j.apjo.2026.100305","DOIUrl":"10.1016/j.apjo.2026.100305","url":null,"abstract":"<div><div>Geographic atrophy (GA), the advanced stage of dry age-related macular degeneration, has transitioned from an untreatable condition to a field of active therapeutic development. This review outlines the key molecular pathways driving GA progression, including complement system dysregulation, oxidative stress, and chronic inflammation. A marked important therapeutic milestone with the first FDA approvals of complement inhibitors, Pegcetacoplan and Avacincaptad pegol, demonstrated a modest but statistically significant slowing of lesion growth. However, these anatomic benefits have not consistently translated into meaningful functional visual improvement, underscoring the need for additional therapeutic strategies. Beyond complement, the therapeutic landscape is rapidly expanding to include oral agents, topical therapies, implant-based delivery systems, subcutaneous injections, and device-based approaches targeting oxidative stress, neuroprotection, mitochondrial dysfunction, lipid metabolism and proteostasis. Emerging modalities, including gene therapy, stem cell–based repair, and bioelectronic implants, aim to move beyond disease slowing toward durable retinal restoration. Despite progress, significant unmet needs persist. Key challenges include treatment burden associated with frequent intravitreal injections, safety considerations, and the persistent disconnect between anatomic endpoints and functional outcomes. These underscore the necessity for future treatments that not only alter disease anatomy but also effectively preserve patients’ vision and improve their quality of life.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"15 2","pages":"Article 100305"},"PeriodicalIF":4.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147493518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Misdiagnosed ocular perforating injury with direct traumatic optic neuropathy from gun pellet confirmed intraoperatively","authors":"Thibaud Garcin ,&nbsp;Mathilde Kaspi ,&nbsp;Nacim Bouheraoua ,&nbsp;Vincent Borderie","doi":"10.1016/j.apjo.2025.100246","DOIUrl":"10.1016/j.apjo.2025.100246","url":null,"abstract":"","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"15 2","pages":"Article 100246"},"PeriodicalIF":4.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of artificial intelligence and robotics in ophthalmic practice","authors":"Dennis S.C. Lam,&nbsp;Haotian Lin,&nbsp;Daniel S.W. Ting","doi":"10.1016/j.apjo.2026.100304","DOIUrl":"10.1016/j.apjo.2026.100304","url":null,"abstract":"","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"15 2","pages":"Article 100304"},"PeriodicalIF":4.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147484302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Faricimab for previously-treated eyes with neovascular age-related macular degeneration with inadequate response – 6-month interim analysis of the FURGGHORN study","authors":"Long T. Phan ,&nbsp;Jennifer Chin ,&nbsp;Geoffrey K. Broadhead ,&nbsp;Thomas H. Hong ,&nbsp;Hemal Mehta ,&nbsp;John H. Chang ,&nbsp;Samantha Fraser-Bell ,&nbsp;Chui Ming Gemmy Cheung ,&nbsp;Christopher Ziyu Sun ,&nbsp;Alan P. Luckie ,&nbsp;Sanjeewa S. Wickremasinghe ,&nbsp;Gerald Liew ,&nbsp;Jagjit S. Gilhotra ,&nbsp;Matthew P. Simunovic ,&nbsp;Nitin Verma ,&nbsp;Andrew A. Chang","doi":"10.1016/j.apjo.2026.100299","DOIUrl":"10.1016/j.apjo.2026.100299","url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate the effect of switching to faricimab therapy patients with neovascular age-related macular degeneration currently treated with anti-VEGF therapy.</div></div><div><h3>Design</h3><div>Phase IV, prospective, single-arm, open-label, multi-center, investigator-initiated clinical trial.</div></div><div><h3>Methods</h3><div>Eligible eyes received four initial doses of faricimab 6 mg/0.05 mL every 4-weeks. From week 12, dosing intervals were increased to eight weeks and then modified according to a treat-and-extend based regimen. This interim analysis reports changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), retinal fluid proportions, and the incidence of adverse events from baseline through to week 24.</div></div><div><h3>Results</h3><div>One-hundred-and-two patients of mean age 76.0 years were recruited from 12 sites across Australia and Singapore. Baseline BCVA was 72 Early Treatment Diabetic Retinopathy Study letters and baseline CST was 384 µm. Seventy-two percent of eyes were being treated with aflibercept 2 mg and 28% with ranibizumab. After switching to faricimab, mean BCVA change was + 1.9 letters at week 12 (<em>P</em> &lt; 0.001), and + 1.9 letters at week 24 (<em>P</em> &lt; 0.001). Mean CST change was −83.9 µm at week 12 (<em>P</em> &lt; 0.001), and −82.2 µm at week 24 (<em>P</em> &lt; 0.001). The proportion of eyes with fluid resolution was 54% at week 12, and 59% at week 24. The proportion of eyes assigned to 4-weekly, 8-weekly, and 12-weekly treatment intervals were 16%, 35% and 49% respectively at week 24. Anterior chamber inflammation occurred in one eye with no cases of vasculitis or occlusive retinitis.</div></div><div><h3>Conclusions</h3><div>In this pre-specified interim analysis of a prospective study, patients switching to faricimab experienced improved anatomic outcomes and maintained visual function, with a large proportion assigned extended dosing intervals under a flexible treatment regimen.</div></div><div><h3>Trial registration number</h3><div>ACTRN12623000215628.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"15 2","pages":"Article 100299"},"PeriodicalIF":4.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147363880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of sixteen axial length adjusted intraocular lens power calculation formulas in long Caucasian eyes","authors":"Wiktor Stopyra ,&nbsp;Oleksiy Voytsekhivskyy ,&nbsp;Andrzej Grzybowski","doi":"10.1016/j.apjo.2026.100301","DOIUrl":"10.1016/j.apjo.2026.100301","url":null,"abstract":"<div><h3>Objective</h3><div>To compare the accuracy of sixteen intraocular lens (IOL) power calculation formulas incorporating targeted adjustments or regression-based modifications of axial length (AL) in eyes longer than 26.00 mm.</div></div><div><h3>Design</h3><div>Retrospective observational study.</div></div><div><h3>Methods</h3><div>The data of myopic patients with cataract who underwent uneventful phacoemulsification with in-the-bag implantation of a PARTIAL−RoF narrow IOL between January 2020 and June 2025 were reviewed. Preoperative IOL power was calculated using the IOLMaster 700 with six formulas: Barrett Universal II (BU II), Haigis, Hoffer Q, Holladay 1, Holladay 2, and SRK/T. The implanted IOL power was selected from BU II or SRK/T recommendations. Refraction was measured three months postoperatively. Postoperative IOL power predictions were generated using the following formulas or formula variants: K6, PEARL-DGS, Castrop, Eom, VRF CMAL; Holladay 1 with Wang-Koch 2 center optimization (WK2), modified Wang-Koch (MWK), non-linear regression (NLR), and Fam-adjusted method (F2); SRK/T WK2, SRK/T MWK, SRK/T F2; Holladay 2 NLR; Hoffer Q WK2; Haigis WK2; and Barrett True AL. The primary outcome measures were root mean square absolute error (RMSAE) and the percentage of eyes with prediction error (PE) within ± 0.25 D, ± 0.50 D, ± 0.75 D, and ± 1.00 D.</div></div><div><h3>Results</h3><div>One hundred sixty-four eyes with ALs ranging from 26.04 mm to 29.72 mm were included. RMSAE values across the sixteen formulas ranged from 0.393 (Holladay 1 NLR and SRK/T WK2) to 0.803 (Haigis WK2). The percentage of eyes with PE within ±0.50 D ranged from 35.98% (Haigis WK2) to 81.1% (Holladay 1 NLR). Holladay 1 NLR—followed by SRK/T WK2, Holladay 1 MWK, VRF CMAL, PEARL-DGS, and Eom—demonstrated significantly higher accuracy than most other formulas. Haigis WK2 and Hoffer Q WK2 were the least accurate.</div></div><div><h3>Conclusions</h3><div>Certain modified third-generation formulas (Holladay 1 NLR, SRK/T WK2) achieve accuracy comparable to that of new-generation formulas (PEARL-DGS, K6, VRF CMAL) in IOL power calculations for long eyes. However, some third- and fourth-generation formulas—even after AL-based modification (Hoffer Q WK2, Haigis WK2)—continue to yield suboptimal results in this anatomical range.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"15 2","pages":"Article 100301"},"PeriodicalIF":4.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147375910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “International consensuses and guidelines on etiology, diagnosis, treatment, and future developments of neovascular age-related macular degeneration (nAMD) by the Asia-Pacific Vitreo-retina Society (APVRS), the Asia-Pacific Ocular Imaging Society (APOIS) and the Academy of the Asia-Pacific Professors of Ophthalmology (AAPPO)” [Asia-Pac J Ophthalmol, Available online 29 August 2025, 100242 (2025) DOI:10.1016/j.apjo.2025.100242]","authors":"Timothy Y.Y. Lai ,&nbsp;Keiko Kataoka ,&nbsp;Yi-Ting Hsieh ,&nbsp;Rajendra S. Apte ,&nbsp;Muna Bhende ,&nbsp;Andrew Chang ,&nbsp;Voraporn Chaikitmongkol ,&nbsp;Youxin Chen ,&nbsp;Li Jia Chen ,&nbsp;Gemmy C.M. Cheung ,&nbsp;Jay Chhablani ,&nbsp;Kenneth C.S. Fong ,&nbsp;Robyn H. Guymer ,&nbsp;Fumi Gomi ,&nbsp;Suber S. Huang ,&nbsp;Judy E. Kim ,&nbsp;Gregg T. Kokame ,&nbsp;Adrian Koh ,&nbsp;Xiaoxin Li ,&nbsp;Jennifer I. Lim ,&nbsp;Dennis S.C. Lam","doi":"10.1016/j.apjo.2025.100249","DOIUrl":"10.1016/j.apjo.2025.100249","url":null,"abstract":"","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"15 2","pages":"Article 100249"},"PeriodicalIF":4.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145318135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of self-refraction using a portable device based on badal optics, iREF, in children in southern China: A cross-sectional study","authors":"Hongxi Wang ,&nbsp;Linrong Wu ,&nbsp;Xin Tan ,&nbsp;Man Pan Chin ,&nbsp;Kunliang Qiu ,&nbsp;Yali Du ,&nbsp;Shengjie Yin ,&nbsp;Binyao Chen ,&nbsp;Jiao Jiang ,&nbsp;Hailiu Chen ,&nbsp;Mingzhi Zhang","doi":"10.1016/j.apjo.2026.100294","DOIUrl":"10.1016/j.apjo.2026.100294","url":null,"abstract":"<div><h3>Objective</h3><div>To compare the refractive and visual accuracy between a portable device based on Badal optical system (iREF), noncycloplegic autorefraction, and cycloplegic subjective refraction.</div></div><div><h3>Methods</h3><div>This cross-sectional study enrolled school-children aged 8–18 years in southern China. The operation procedure of self-refraction (SR) using iREF was taught by one researcher, and then the participants used iREF to test the spherical equivalent refraction (SE_SR) by themselves. Then, non-cycloplegic autorefraction (NCAR) was conducted and spherical equivalent (SE_NCAR) was calculated by another researcher. The third researcher, blind to the procedure and results above, performed subjective cycloplegic refraction (CR) and calculated SE_CR.</div></div><div><h3>Results</h3><div>We enrolled 209 participants, with a mean age of 12.13 ± 2.14 years old (males accounting 50.72 %) and a mean SE of −2.91 ± 1.94 D. Bland-Altman plots showed 10 (4.8 %) of the right eye fell outside the 95 % consistency limit of SE_CR and SE_SR. The SE of the right eye by NCAR and SR was −3.03 ± 1.93D and −2.94 ± 1.89D, respectively. The error of SR (-0.03 ± 0.36D) was significantly lower than that of NACR (-0.12 ± 0.31D) (<em>P</em> &lt; 0.001). The absolute error of SR was less than 0.50D in 185 cases (88.5 %), which was not significantly different from that of NCAR (190 cases, 90.9 %) (<em>P</em> = 0.487). High myopia (SE &lt; −6.00 D) and high astigmatism (over 2.00 D) had more obvious errors than other groups.</div></div><div><h3>Conclusion</h3><div>There is high consistency of the spherical equivalent measured by iREF self-refraction and cycloplegic refraction, while the accuracy diminishes in patients with high refractive errors.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"15 2","pages":"Article 100294"},"PeriodicalIF":4.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146099760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Constructive critique on consensus guidelines for posterior chamber phakic intraocular lens implantation","authors":"Parth Aphale ,&nbsp;Himanshu Shekhar ,&nbsp;Shashank Dokania","doi":"10.1016/j.apjo.2025.100250","DOIUrl":"10.1016/j.apjo.2025.100250","url":null,"abstract":"","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"15 2","pages":"Article 100250"},"PeriodicalIF":4.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145285533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}